“Stevens-Johnson Syndrome After Armodafinil Use”, 2018-05-15 (; backlinks; similar):
We present the case of a 21-year-old woman in whom Stevens-Johnson syndrome (SJS) developed after initiation of armodafinil.
Although this rare and life-threatening reaction is listed on armodafinil’s label, no cases have been reported in the literature. This case, in addition to an update of the drug’s label after post-marketing research, both support the link between armodafinil and SJS.
Providers should maintain a high clinical suspicion for SJS when starting therapy to minimize associated morbidity and mortality by discontinuing armodafinil at the onset of first symptoms.